B7H3 increases ferroptosis resistance by inhibiting cholesterol metabolism in colorectal cancer
Cancer Science · 2023-11 · 114 (11) · 4225-4236
DOI: 10.1111/cas.15944 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 03.09.2023. Verfasst von Haiyan Jin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Ferroptosis. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gusu Talent Project of Suzhou, Jiangsu Provincial Medical Key Discipline, Natural Science Foundation Project of the Doctoral Cultivation Program.
Abstract (Originalsprache)
Ferroptosis, a newly discovered form of regulated cell death, has been reported to be associated with multiple cancers, including colorectal cancer (CRC). However, the underlying molecular mechanism is still unclear. In this study, we identified B7H3 as a potential regulator of ferroptosis resistance in CRC. B7H3 knockdown decreased but B7H3 overexpression increased the ferroptosis resistance of CRC cells, as evidenced by the expression of ferroptosis‐associated genes ( PTGS2 , FTL , FTH , and GPX4 ) and the levels of important indicators of ferroptosis (malondialdehyde, iron load). Moreover, B7H3 promoted ferroptosis resistance by regulating sterol regulatory element binding protein 2 (SREBP2)‐mediated cholesterol metabolism. Both exogenous cholesterol supplementation and treatment with the SREBP2 inhibitor betulin reversed the effect of B7H3 on ferroptosis in CRC cells. Furthermore, we verified that B7H3 downregulated SREBP2 expression by activating the AKT pathway. Additionally, multiplex immunohistochemistry was carried out to show the expression of B7H3, prostaglandin‐endoperoxide synthase 2, and SREBP2 in CRC tumor tissues, which was associated with the prognosis of patients with CRC. In summary, our findings reveal a role for B7H3 in regulating ferroptosis by controlling cholesterol metabolism in CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China.
- Jiangsu Key Laboratory of Clinical Immunology, Soochow University, Suzhou, China.
- Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou, China.
- Pasteurien College, Suzhou Medical College, Soochow University, Suzhou, China.
- Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
ORCID-Profile: Xiaoshan Liu, Tongguo Shi
Förderung
- Gusu Talent Project of Suzhou
- Jiangsu Provincial Medical Key Discipline
- Natural Science Foundation Project of the Doctoral Cultivation Program
- Suzhou "Science and Education Revitalize Health" Youth Science and Technology Project
- Suzhou Natural Science Foundation
- the key project of Jiangsu Provincial Health and wellness Commission
- The National Natural Science Foundation of China
- Natural Science Foundation of Suzhou City
Zitieren
APA
Jin, H., Zhu, M., Zhang, D., Liu, X., Guo, Y., Xia, L., Chen, Y., Chen, Y., Xu, R., Liu, C., Xi, Q., Xia, S., Shi, T., & Zhang, G. (2023). B7H3 increases ferroptosis resistance by inhibiting cholesterol metabolism in colorectal cancer. Cancer Science, 114(11), 4225-4236. https://doi.org/10.1111/cas.15944
Vancouver
Jin H, Zhu M, Zhang D, Liu X, Guo Y, Xia L, et al. B7H3 increases ferroptosis resistance by inhibiting cholesterol metabolism in colorectal cancer. Cancer Science. 2023;114(11):4225-4236. doi:10.1111/cas.15944
BibTeX
@article{Jin2023,
author = {Jin, Haiyan and Zhu, Mengxin and Zhang, Dongze and Liu, Xiaoshan and Guo, Yuesheng and Xia, Lu and Chen, Yanjun and Chen, Yuqi and Xu, Ruyan and Liu, Cuiping and Xi, Qinhua and Xia, Suhua and Shi, Tongguo and Zhang, Guangbo},
title = {B7H3 increases ferroptosis resistance by inhibiting cholesterol metabolism in colorectal cancer},
journal = {Cancer Science},
year = {2023},
volume = {114},
number = {11},
pages = {4225--4236},
doi = {10.1111/cas.15944}
}
EUVIMED